New combo aims to cut nausea in obesity treatment
NCT ID NCT07411560
First seen Feb 20, 2026 · Last updated Apr 25, 2026 · Updated 6 times
Summary
This study tests whether combining two experimental drugs (cagrilintide and NNC0480-0389) causes fewer stomach side effects like nausea and vomiting than cagrilintide alone. About 100 women with overweight or obesity will receive both combos at different times. The goal is to see if the combination is safer and better tolerated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Parexel Research Unit
RECRUITINGHarrow, Middlesex, HA1 3UJ, United Kingdom
Conditions
Explore the condition pages connected to this study.